A5045878405- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Lipids, and Metabolism
- Protein Degradation and Inhibitors
- Cancer Risks and Factors
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- Breast Cancer Treatment Studies
- Cerebral Palsy and Movement Disorders
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
- Stroke Rehabilitation and Recovery
- Cancer-related Molecular Pathways
- Histone Deacetylase Inhibitors Research
- Acute Ischemic Stroke Management
- Estrogen and related hormone effects
- PI3K/AKT/mTOR signaling in cancer
Hubei Cancer Hospital
2022-2025
Huazhong University of Science and Technology
2022-2024
Tongji Hospital
2022
Abstract Objective To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, docetaxel compared with placebo, for untreated HER2 positive metastatic breast cancer. Design Randomised, double blind, placebo controlled, multicentre, phase 3 trial. Setting 40 centres in China between 6 May 2019 17 January 2022. Participants 590 female patients (median age 52 (interquartile range 46-58) years) Interventions Eligible...
Abstract Background The global BOLERO-2 trial established the efficacy and safety of combination everolimus (EVE) exemestane (EXE) in treatment estrogen receptor positive (ER +), HER2-, advanced breast cancer (ABC). BOLERO-5 investigated this a Chinese population (NCT03312738). Methods is randomized, double-blind, multicenter, placebo controlled, phase II comparing EVE (10 mg/day) or (PBO) with EXE (25 mg/day). primary endpoint was progression-free survival (PFS) per investigator assessment....
Abstract Background: SHR-A1811 is an ADC comprised of a humanized anti-HER2 monoclonal antibody (trastuzumab), cleavable linker, and DNA topoisomerase I inhibitor payload. Here we assessed in HER2-expressing/mutated unresectable, advanced, or metastatic solid tumors. Methods: Pts were eligible if they had HER2 positive breast cancer (BC), gastric/GEJ carcinoma, low-expressing BC, NSCLC, other tumors, refractory intolerant to standard therapy. at doses 1.0-8.0 mg/kg was given Q3W (IV). The...
Abstract Background: Patients (pts) with mTNBC have limited treatment options and poor prognosis. The estimated median overall survival (OS) of pts is 12 to 18 months (mo) after diagnosis. SKB264, an antibody drug conjugate (ADC) composed anti-TROP2 coupled a cytotoxic belotecan-derivative via novel linker average Drug Antibody Ratio (DAR) 7.4, has shown promising anti-tumor activity tolerable safety profile in (Yin, Y. et al. SABCS 2022). Here, we report the updated data from Phase 2...
Abstract Background: The therapeutic options for patients (pts) with previously treated metastatic TNBC are limited compared other breast cancer subtypes. SKB264 is an antibody drug conjugate (ADC) composed of anti-TROP2 coupled to the cytotoxic belotecan-derivative via a novel linker. Here, we present results from Phase 2 expansion cohort pts mTNBC (NCT04152499). Methods: Pts were enrolled receive 4 mg/kg Q2W or 5 in non-randomized fashion until disease progression/unacceptable toxicity....
Pyrotinib, an irreversible pan-ErbB inhibitor, has been approved for treating HER2-positive advanced breast cancer in China. We conducted a nationwide, prospective observational study to examine the real-world data of pyrotinib-based therapy this population. Patients from 61 sites across China were included. Pyrotinib-based regimens prescribed at local physician's discretion. Demographics, treatment patterns, prognosis and safety evaluated. The primary outcome was progression-free survival...
Abstract Background Entinostat is a novel, potent, once weekly, orally bioavailable, class I selective histone deacetylase (HDAC) inhibitor. In previous Phase II study, the combination of entinostat with exemestane showed significant improvement overall survival in patients advanced hormone receptor (HR) positive breast cancer. To verify and further confirm benefit HDAC inhibitor we designed randomized, controlled trial to assess efficacy safety larger population Chinese advanced, HR Methods...
Abstract Objective Stroke causes serious physical disability with impaired quality of life (QoL) and heavy burden on health. The goal this study is to explore the QoL typologies their predicting factors in physically disabled stroke survivors machine learning approach. Methods Non‐negative matrix factorization (NMF) was applied clustering 308 rural China based responses short form 36 (SF‐36) assessment life. Principal component analysis (PCA) conducted differentiate subtypes, Boruta...
Abstract Background Breast cancer is the most frequently diagnosed and 5th common cause of cancer-related death in Chinese women with over 416,000 new cases 117,000 deaths estimated 2020. Triple-negative breast (TNBC) represents 10%-20% cancer. Sacituzumab govitecan (SG) a Trop-2-directed antibody-drug conjugate approved for second-line or later (2L+) treatment metastatic (m)TNBC multiple countries, including US China. In pivotal phase 3 study ASCENT, which enrolled predominantly non-Asian...
Abstract Background: Pertuzumab is a recombinant humanized monoclonal antibody targeting the extracellular dimerization domain II of HER2. On September 30, 2013, FDA have granted accelerated approval pertuzumab regimen for neoadjuvant treatment patients (pts) with high-risk, HER2-positive early stage breast cancer. TQB2440 (Perjeta®, Roche) biosimilar. This study aimed to compare efficacy and safety reference combined trastuzumab docetaxel in pts or locally advanced Methods: In this...
2 Background: ESG401, a novel ADC comprising humanized anti-TROP2 IgG1 monoclonal antibody conjugated to SN-38, with Drug-Antibody Ratio of 8 and stable cleavable linker, demonstrated preliminary efficacy tolerability in the Phase Ia trial (Ma, ASCO 2023). This report presents updated results from first-line mTNBC cohort Ib patients brain metastases. Methods: Patients (pts) aged ≥18 years confirmed local advanced/unresectable or metastatic TNBC, without prior treatment, received ESG401 (16...
Abstract Background: Pyrotinib, a newly-developed irreversible pan-ErbB inhibitor, has shown promising antitumor activity and acceptable tolerability in phase 1-3 studies. However, findings from randomized clinical trials may have limited generalizability to patients treated routine practice. Herein, we conducted this multicenter real-world study examine the treatment patterns, effectiveness safety of pyrotinib-based therapy human epidermal growth factor receptor 2 (HER2)-positive breast...
Abstract Purpose: This study aimed to compare the demographic and clinical characteristics of pregnancy-associated breast cancer (PABC) non-PABC patients, analyze prognostic factors. Methods: PABC patients ≤ 40 years old who were treated in three large tertiary institutions from January 1, 2016 August 2020 included. The population tumor collected, their survival followed up. For each case, a patient was matched as control. Results: A total 69 included study. Compared with group, stage later....